Form 8-K - Current report:
SEC Accession No. 0001387131-23-006702
Filing Date
2023-05-22
Accepted
2023-05-22 07:05:22
Documents
13
Period of Report
2023-05-22
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp_8k-052223.htm   iXBRL 8-K 29864
2 PRESS RELEASE ex99-01.htm EX-99.01 21303
  Complete submission text file 0001387131-23-006702.txt   231841

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20230522.xsd EX-101.SCH 2935
4 XBRL LABEL FILE tnxp-20230522_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tnxp-20230522_pre.xml EX-101.PRE 22343
7 EXTRACTED XBRL INSTANCE DOCUMENT tnxp_8k-052223_htm.xml XML 3468
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 23942413
SIC: 2834 Pharmaceutical Preparations